Home › Trial NCT04671420
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.
- Trial IDNCT04671420
- StatusWithdrawn
- PhasePhase 3
- Study typeInterventional
- SponsorShanghai Henlius Biotech
- Enrollment—
- Start date2020-10
- ConditionsCD20-positive Follicular Lymphoma, With Low Tumour Burden
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.